“Now our vision is to become the most valued and trusted medicines company in the world. That's a long-term vision.”
Vasant Narasimhan, CEO
$NVS “over the last five years, we've done over $100 billion of transactions – or planned transactions to come to a 100% innovative medicines company. And with each one of these, we really strive to do things in a shareholder-friendly way”
“One key priority of ours is to improve our position in the U.S. We are the number one player in Europe. We will be one of the top three players in Japan and China.”
“we have 6 major in-market brands, each with multibillion-dollar potential in sales, most of which have long LOE time lines; three, additional multibillion-dollar assets,”
“And what we expect that to deliver is consistent 4% sales growth and over 40% core margin. It's important that 40% margin is for the total company, inclusive of the corporate cost of being a conglomerate. So that's a pretty big step up from where we are today.”
We analysed Novartis AG in our newsletter back in November.
Novartis link